A management-led syndicate of prominent investors acquired a majority stake in Histosonics Inc. that values the company at ...

With half-year industry financings down 59% from last year, and a U.S. administration supportive of cryptocurrencies, ...

The difference between the origin of Alzheimer's disease (AD) and its symptoms is an obstacle to finding effective treatments ...

Bio-Techne Corp. plans to sell its Exosome Diagnostics Inc. business to Mdxhealth SA for $15 million plus royalty payments, a ...

Jazz Pharmaceuticals plc is prepped and ready for launch following U.S. FDA accelerated approval of dordaviprone as the first systemic therapy for H3 K27M-mutant diffuse glioma. Branded Modeyso, the ...

Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding subtypes in Alzheimer’s disease is all but imperative.

In the tumor microenvironment, cancer cells activate various signaling pathways to promote their growth. This includes the ...

Precision medicine is becoming a reality in Asia Pacific as more targeted therapies are being developed that are tailored to ...

The U.S. Department of Health and Human Services has tapped Sean Keveney for the job of FDA chief counsel, but the recent ...

T-cell engagers (TCEs) are a new class of immuno-oncology therapies that have proven effective for the treatment of both ...

Glioblastoma, one of the most lethal brain cancers, remains a challenge to treat despite advancements in conventional ...

Chronic infection with hepatitis B virus affects around a quarter of a billion people globally, and it can increase risk of ...